Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,184
  • Shares Outstanding, K 144,955
  • Annual Sales, $ 148,760 K
  • Annual Income, $ -264,520 K
  • 60-Month Beta 0.24
  • Price/Sales 0.32
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.75
  • Most Recent Earnings -0.39 on 11/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 240.90% ( +6.92%)
  • Historical Volatility 375.91%
  • IV Percentile 91%
  • IV Rank 52.35%
  • IV High 417.65% on 11/10/22
  • IV Low 46.71% on 03/11/22
  • Put/Call Vol Ratio 0.02
  • Today's Volume 3,471
  • Volume Avg (30-Day) 3,141
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 95,927
  • Open Int (30-Day) 93,570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.37
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +32.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2270 +51.45%
on 11/09/22
0.9900 -65.27%
on 11/08/22
-0.5462 (-61.37%)
since 11/02/22
3-Month
0.2270 +51.45%
on 11/09/22
1.5850 -78.31%
on 09/12/22
-0.7862 (-69.58%)
since 09/02/22
52-Week
0.2270 +51.45%
on 11/09/22
3.3200 -89.64%
on 12/21/21
-2.7662 (-88.95%)
since 12/02/21

Most Recent Stories

More News
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 68.47 (+0.19%)
MRK : 110.04 (+0.22%)
ANGN : 0.9200 (+12.20%)
CLVS : 0.3438 (-4.50%)
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings...

CLVS : 0.3438 (-4.50%)
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

PFE : 50.91 (-0.33%)
CLVS : 0.3438 (-4.50%)
PBYI : 4.45 (-2.41%)
SNDX : 25.07 (+0.16%)
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 0.3438 (-4.50%)
INVO : 0.8068 (-1.86%)
Clovis: Q3 Earnings Snapshot

Clovis: Q3 Earnings Snapshot

CLVS : 0.3438 (-4.50%)
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound,...

ONCY : 1.85 (-12.74%)
ONC.TO : 2.50 (-11.35%)
CLVS : 0.3438 (-4.50%)
OPK : 1.4700 (+0.68%)
CRDF : 1.5700 (+6.08%)
MRK : 110.04 (+0.22%)
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The...

CLVS : 0.3438 (-4.50%)
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GH : 53.81 (+2.67%)
CLVS : 0.3438 (-4.50%)
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CLVS : 0.3438 (-4.50%)
INCY : 83.13 (+3.04%)
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35 th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored...

CLVS : 0.3438 (-4.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with...

See More

Key Turning Points

3rd Resistance Point 0.3850
2nd Resistance Point 0.3725
1st Resistance Point 0.3581
Last Price 0.3438
1st Support Level 0.3312
2nd Support Level 0.3187
3rd Support Level 0.3043

See More

52-Week High 3.3200
Fibonacci 61.8% 2.1385
Fibonacci 50% 1.7735
Fibonacci 38.2% 1.4085
Last Price 0.3438
52-Week Low 0.2270

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar